April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Intravitreal Aflibercept in Eyes with Neovascular AMD Requiring Frequent Retreatment with Intravitreal Bevacizumab or Ranibizumab
Author Affiliations & Notes
  • Mariana Rossi Thorell
    Ophthalmology, Bascom Palmer Eye Institute - University of Miami, Miami, FL
  • Renata Portella Nunes
    Ophthalmology, Bascom Palmer Eye Institute - University of Miami, Miami, FL
  • Giovanni Gregori
    Ophthalmology, Bascom Palmer Eye Institute - University of Miami, Miami, FL
  • William J Feuer
    Ophthalmology, Bascom Palmer Eye Institute - University of Miami, Miami, FL
  • Philip J Rosenfeld
    Ophthalmology, Bascom Palmer Eye Institute - University of Miami, Miami, FL
  • Footnotes
    Commercial Relationships Mariana Rossi Thorell, Carl Zeiss Meditec (F); Renata Portella Nunes, Carl Zeiss Meditec (F); Giovanni Gregori, Carl Zeiss Meditec (F), Carl Zeiss Meditec (P); William Feuer, None; Philip Rosenfeld, Carl Zeiss Meditec (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 4987. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mariana Rossi Thorell, Renata Portella Nunes, Giovanni Gregori, William J Feuer, Philip J Rosenfeld; Intravitreal Aflibercept in Eyes with Neovascular AMD Requiring Frequent Retreatment with Intravitreal Bevacizumab or Ranibizumab. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4987. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the effects of switching from bevacizumab or ranibizumab to aflibercept in eyes with neovascular AMD requiring frequent retreatment every 4 to 6 weeks.

Methods: A retrospective review was performed on patients with neovascular AMD undergoing anti-VEGF therapy for at least one year with persistent or recurrent macular fluid requiring retreatment every 4 to 6 weeks with intravitreal bevacizumab or ranibizumab prior to the switch to intravitreal aflibercept. Patients were followed for a minimum of 6 months after the switch. All patients were treated using a treat-and-extend strategy, and the treatment interval immediately after the switch was the same as the interval immediately before the switch. Best-corrected visual acuity (BCVA), number of injections, and SDOCT imaging measurements were collected.

Results: A total of 72 eyes of 64 patients with neovascular AMD met the inclusion criteria during the study period. The mean duration of anti-VEGF therapy prior to the first aflibercept injection was 44.5 months (range 13.8-104.7). The mean number of total injections was 30.5 for the entire treatment period prior to the switch and 9.9 for the 12 months prior to the switch. The average number of anti-VEGF injections was reduced by 0.58 during the 6 months after the first aflibercept injection compared with the 6 months prior to the first aflibercept injection (p<0.001). BCVA increased by 0.5 letters during the 6 months after the switch to aflibercept, which was not statistically different from the 1.0 letter increase during the 6 months before the switch to aflibercept (p=0.75). Central retinal thickness did improve from 257.4 microns to 239.7 microns during the 6 months after the switch to aflibercept (p<0.001). Sixty-nine of the 72 eyes had vascularized retinal pigment epithelial detachments (PEDs). The change in PED cube-root volume 6 months after the switch to aflibercept was statistically significant (-0.08 mm, p=0.001) compared with the change in PED volume 6 months before the switch (0.02 mm, p=0.21).

Conclusions: The number of injections, PED volume, and central retinal thickness decreased significantly following the switch to aflibercept in eyes undergoing frequent reinjection using a treat-and-extend treatment strategy, but the BCVA did not change during the study period.

Keywords: 412 age-related macular degeneration • 561 injection • 701 retinal pigment epithelium  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×